Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne, David R W
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. [electronic resource] - Journal of the American Society of Nephrology : JASN Sep 2017 - 2756-2767 p. digital
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
1533-3450
10.1681/ASN.2016111179 doi
Adult
Aged
Aniline Compounds--adverse effects
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis--drug therapy
Cyclophosphamide--therapeutic use
Double-Blind Method
Drug Therapy, Combination--adverse effects
Female
Glucocorticoids--administration & dosage
Humans
Immunosuppressive Agents--therapeutic use
Male
Middle Aged
Nipecotic Acids--adverse effects
Prednisone--administration & dosage
Receptor, Anaphylatoxin C5a--antagonists & inhibitors
Rituximab--therapeutic use
Severity of Illness Index
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. [electronic resource] - Journal of the American Society of Nephrology : JASN Sep 2017 - 2756-2767 p. digital
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
1533-3450
10.1681/ASN.2016111179 doi
Adult
Aged
Aniline Compounds--adverse effects
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis--drug therapy
Cyclophosphamide--therapeutic use
Double-Blind Method
Drug Therapy, Combination--adverse effects
Female
Glucocorticoids--administration & dosage
Humans
Immunosuppressive Agents--therapeutic use
Male
Middle Aged
Nipecotic Acids--adverse effects
Prednisone--administration & dosage
Receptor, Anaphylatoxin C5a--antagonists & inhibitors
Rituximab--therapeutic use
Severity of Illness Index